Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at Leede Financial issued their FY2024 earnings estimates for Oncolytics Biotech in a note issued to investors on Wednesday, November 13th. Leede Financial analyst D. Loe forecasts that the company will earn ($0.34) per share for the year. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech's FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.05) EPS.
Separately, Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday.
View Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Up 0.7 %
Shares of ONC traded up C$0.01 during mid-day trading on Monday, hitting C$1.39. The company's stock had a trading volume of 17,762 shares, compared to its average volume of 70,788. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The company's 50-day moving average is C$1.50 and its 200-day moving average is C$1.45. Oncolytics Biotech has a 52-week low of C$1.15 and a 52-week high of C$2.32. The firm has a market capitalization of C$106.84 million, a price-to-earnings ratio of -3.63 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
